In a troubling demonstration of corporate influence on regulatory processes, newly released government records reveal that senior officials from the Environmental Protection Agency (EPA) engaged in discussions with Bayer’s CEO, Bill Anderson, regarding legal strategies tied to the company’s controversial glyphosate herbicides, such as Roundup. These meetings occurred just months prior to the Trump administration taking decisive actions that appear to bolster Bayer’s position in ongoing litigation involving cancer claims made by thousands of consumers.
Meeting of Minds
On 17 June 2025, Anderson met with key EPA personnel, including Lee Zeldin, the agency’s administrator, and other top officials. The meeting focused on “litigation” matters, particularly the potential for the Supreme Court to intervene in Bayer’s ongoing legal challenges. This gathering took place as Bayer sought to mitigate the financial fallout from lawsuits alleging that its glyphosate products are linked to cancer—a claim backed by numerous scientific studies.
Bayer’s primary legal strategy hinges on the argument that if the EPA does not mandate a cancer warning on glyphosate products, the company cannot be held liable for failing to provide such warnings. While some courts have sided with Bayer, many others, including the Biden administration’s solicitor general, have rejected this preemption argument. The stark contrast in approaches between the Trump and Biden administrations highlights the political dimensions of this contentious issue.
Regulatory Support for Corporate Interests
The implications of the 17 June meeting extend beyond mere discussion; they appear to have catalysed a series of supportive actions from the Trump administration. Following the meeting, the administration actively sought to endorse Bayer’s position in the courts. A filing by the Trump-appointed solicitor general on 1 December 2025 urged the Supreme Court to consider Bayer’s case, leading to a scheduled hearing on 27 April 2026.
Moreover, the White House invoked the Defense Production Act on 18 February 2026 to safeguard glyphosate production and extend “immunity” to manufacturers like Bayer. This pattern of regulatory alignment raises questions about the integrity of the EPA’s commitment to public health versus corporate profit.
Voices of Concern
Critics are alarmed by the apparent prioritisation of corporate interests over public welfare. Nathan Donley, environmental health science director for the Center for Biological Diversity, expressed concern over the growing influence of pesticide companies on regulatory bodies. “When the CEO of one of the largest companies in the world meets with political appointees in a US regulatory office, it shows just how much power these corporations wield,” he stated.
Legal experts echo these sentiments, pointing out the unequal access to regulatory discussions. Whitney Di Bona, a consumer safety advocate, highlighted the lack of opportunities for affected individuals to be heard. “It’s worrying that the CEO of a major pesticide company can have private meetings with the EPA to discuss limiting liability while those harmed by their products remain unheard,” she remarked.
The Broader Context
The relationship between industry leaders and government regulators is not new, but this incident starkly illustrates the potential consequences of such interactions. Activists like Zen Honeycutt, founder of Moms Across America, have long pointed to the problematic nature of corporate influence on public health regulations. “Coercion by chemical companies on our regulatory agencies is nothing new,” she noted, emphasising the need for transparency and accountability in these processes.
The concerns raised by this meeting and the subsequent actions by the Trump administration highlight a broader issue of corporate power in shaping regulatory frameworks. As Bayer continues to face mounting legal challenges, the question remains: who is truly being protected—the public or corporate interests?
Why it Matters
The revelations surrounding Bayer’s interactions with the EPA underscore a critical moment in the ongoing battle over pesticide regulation and public health. With the potential for the Supreme Court to weigh in on pivotal litigation, the outcome could set a precedent that not only affects Bayer but also the future of environmental safety and consumer protection. As the fight against corporate influence in policymaking intensifies, it is imperative for citizens to remain vigilant and advocate for a regulatory landscape that prioritises health and safety over corporate profits.
